BioSpace News Archive

The Foundation for Sickle Cell Disease Research (FSCDR), the US’s first outpatient center exclusively dedicated to the treatment of and innovative research for SCD, today announced the 16th Annual Sickle Cell Disease Research and Educational Symposium, and the 45th Annual Sickle Cell Disease Scientific Meeting.

CorePath is excited to announce a partnership with Cizzle Biotechnology, a UK based diagnostics developer, to develop and offer a proprietary early-stage lung cancer test throughout the United States.

Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference.

According to QY Research Medical, the longevity and anti-senescence therapy market size is projected to reach US$ 44.2 billion by 2030, growing at a CAGR of 6.4% from 2021 to 2030.

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”

Sosei Group Corporation announces it has expanded its UK R&D operations into a second site within Granta Park, Cambridge, to The Cori Building, previously occupied by Cancer Research UK.

Biosynth Carbosynth, a supplier of critical materials to the life science industry, announces the acquisition of Aalto Bio Reagents, a leading developer and provider of biological materials to the in-vitro diagnostic and vaccine development industry in the field of emerging disease.

GenScript USA Inc., a subsidiary of GenScript Biotech Corporation, a world-leading biotechnology company, has reached an agreement with EUROIMMUN US Inc., a PerkinElmer Company, for the distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in the United States and Canada.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing and granted Priority Review of its New Drug Application for omaveloxolone for the treatment of patients with Friedreich’s ataxia.

FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.